Treatment of Inherited Factor VII Deficiency
NCT01269138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223
Last updated 2012-11-27
Summary
FVII deficiency is a rare coagulation disorder. A limited number of patients are found in most treatment centres and countries. Treatment demands vary considerably amongst FVII deficient patients. Therefore, regular clinical studies will meet with recruitment problems in this particular patient population. The present study intends to elucidate the bleeding patterns in a well-defined collective of FVII deficiency patients who are carefully characterised, to document the actual use of different treatment modalities in different subgroups and to evaluate the efficacy and safety of current available treatment modalities in bleedings, surgery and prophylaxis. The purpose is to gain some evidence based knowledge of treatment of patients with FVII deficiency - an area where treatment decisions are made more on personal clinical experience than on consolidated clinical evidence.
This study intends to register treatment practices as they are actually performed - in a structured and documented way.
Conditions
- Factor VII Deficiency
Interventions
- DRUG
-
plasma derived Factor VII
Treatment of bleeding episodes,treatment during surgery and prophylaxis
- DRUG
-
recombinant FVIIa
Treatment of bleeding episodes,treatment during surgery and prophylaxis
- DRUG
-
Fresh Frozen Plasma
Treatment of bleeding episodes,treatment during surgery and prophylaxis
- DRUG
-
Activated Prothrombin Complex Concentrates
Treatment of bleeding episodes,treatment during surgery and prophylaxis
- DRUG
-
Virus Inactivated plasma
Treatment of bleeding episodes,treatment during surgery and prophylaxis
Sponsors & Collaborators
-
TRIB s.r.l.
collaborator UNKNOWN -
University of L'Aquila
lead OTHER
Principal Investigators
-
guglielmo mariani, md · University of L'Aquila
Eligibility
- Min Age
- 1 Day
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Completion
- 2012-11-30
Countries
- Italy
Study Locations
More Related Trials
-
Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
NCT00770718 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
NCT01562587 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
NCT01439971 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
NCT02020369 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT00426803 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
NCT04768699 ·Status: UNKNOWN ·Phase: PHASE1
-
Recombinant Factor VII for Intractable Postpartum Haemorrhage
NCT05298826 ·Status: COMPLETED
-
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
NCT05487976 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
NCT00108758 ·Status: COMPLETED ·Phase: PHASE2
-
National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology
NCT01532661 ·Status: COMPLETED
-
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
NCT00375323 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
NCT00703911 ·Status: COMPLETED
-
Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
NCT00922792 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
NCT00123591 ·Status: COMPLETED ·Phase: PHASE2
-
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
NCT01105546 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
NCT01561391 ·Status: COMPLETED ·Phase: PHASE4
-
PROPACT: Retrospective Prophylaxis Patient Case Collection
NCT00882778 ·Status: COMPLETED
-
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
NCT01708564 ·Status: COMPLETED ·Phase: PHASE1
-
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT01712438 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers
NCT01542619 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00885742 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
NCT01562158 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
NCT00697320 ·Status: COMPLETED
-
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
NCT01234545 ·Status: COMPLETED